Current Edition

Broadening the Treatment Horizon for Heart Failure Patients

Through its issuance of recommendations and regulatory decisions concerning medical products, the US Food and Drug Administration (FDA) typically considers the “unmet medical need” surrounding a particular disease or condition. In the most extreme circumstances, as with many rare diseases, FDA-approved therapies may not be available. There are also numerous contexts, however, in which treatments are approved, but a need still exists for refinement to better target the patient population – such is the case for heart failure (HF) drugs. Deborah Komlos at Clarivate, explains more about the treatment horizon for heart failure patients.